In a report released on March 19, Michael Okunewitch from Maxim Group maintained a Buy rating on Mainz Biomed B.V. (MYNZ – Research Report), with a price target of $14.00.
Michael Okunewitch has given his Buy rating due to a combination of factors, primarily focusing on Mainz Biomed’s strategic collaboration with Liquid Biosciences. This partnership grants Mainz access to a portfolio of mRNA biomarkers, which have demonstrated high sensitivity and specificity in detecting pancreatic cancer through blood-based screening tests.
Pancreatic cancer is notoriously difficult to detect early, with most cases identified at a late stage, making the development of a highly accurate screening test a significant advancement. The biomarkers from Liquid Biosciences, if successfully integrated into Mainz’s product, could position the company as a leader in this critical area. Additionally, Mainz’s existing efforts in pancreatic cancer detection, such as the PancAlert program, further bolster their pipeline and potential market impact, supporting the Buy recommendation.
MYNZ’s price has also changed dramatically for the past six months – from $0.249 to $4.270, which is a 1614.86% increase.